Center Georges-Francois Leclerc

Dijon, Other 21079

0 studies enrolling now · 2 studies all time

What they study most

HER2 Positive Breast Cancer, Metastatic Colorectal Adenocarcinoma

Studies at this site

• A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Running, not enrolling
• Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer — Completed